Eton Pharmaceuticals Inc (ETON) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Eton Pharmaceuticals Inc (ETON) has a cash flow conversion efficiency ratio of 0.242x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($7.41 Million) by net assets ($30.61 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Eton Pharmaceuticals Inc (ETON) balance sheet quality index to measure how much of total assets are equity-financed.
Eton Pharmaceuticals Inc - Cash Flow Conversion Efficiency Trend (2017–2025)
This chart illustrates how Eton Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Eton Pharmaceuticals Inc (ETON) cash flow quality to evaluate the quality of earnings relative to operating cash generation.
Eton Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Eton Pharmaceuticals Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Bangkok Chain Hospital Public Company Limited
BK:BCH-R
|
0.032x |
|
Focus Lightings Tech Co Ltd
SHE:300708
|
0.000x |
|
Huadian Heavy Industries Co
SHG:601226
|
-0.055x |
|
Danya Cebus
TA:DNYA
|
-0.046x |
|
Hbt Financial Inc
NASDAQ:HBT
|
0.032x |
|
BP PLC
LSE:BP
|
0.103x |
|
Jiangxi Guotai Civilian
SHG:603977
|
-0.035x |
|
Invisio Communications AB
ST:IVSO
|
0.047x |
Annual Cash Flow Conversion Efficiency for Eton Pharmaceuticals Inc (2017–2025)
The table below shows the annual cash flow conversion efficiency of Eton Pharmaceuticals Inc from 2017 to 2025. For the full company profile with market capitalisation and key ratios, see ETON market cap overview.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $26.15 Million | $10.52 Million | 0.402x | +914.39% |
| 2024-12-31 | $24.43 Million | $969.00K | 0.040x | -90.99% |
| 2023-12-31 | $15.48 Million | $6.82 Million | 0.440x | +19.45% |
| 2022-12-31 | $13.08 Million | $4.82 Million | 0.369x | +237.66% |
| 2021-12-31 | $17.63 Million | $-4.72 Million | -0.268x | +81.23% |
| 2020-12-31 | $15.66 Million | $-22.35 Million | -1.427x | +16.50% |
| 2019-12-31 | $10.55 Million | $-18.03 Million | -1.709x | -451.77% |
| 2018-12-31 | $26.30 Million | $-8.14 Million | -0.310x | +20.39% |
| 2017-12-31 | $12.13 Million | $-4.72 Million | -0.389x | -- |
About Eton Pharmaceuticals Inc
Eton Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing treatments for rare diseases. Its commercial rare disease products include Increlex for the treatment of severe primary igf-1 deficiency; Alkindi Sprinkle for adrenal insufficiency; Khindivi for adrenocortical insufficiency; Galzin for Wilson disease; PKU Golike for phenylketonuria; Carglumic Acid for … Read more